Liquidia Corp
NASDAQ:LQDA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Liquidia Corp
NASDAQ:LQDA
|
2.9B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
294.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Liquidia Corp is 89.1%, which is above its 3-year median of 74.8%.
Over the last 3 years, Liquidia Corp’s Gross Margin has increased from 79.1% to 89.1%. During this period, it reached a low of 58% on Dec 31, 2024 and a high of 89.1% on Sep 30, 2025.
